iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,883 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,883 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the transaction, the chief executive officer now directly owns 153,903 shares in the company, valued at $1,542,108.06. The trade was a 22.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Michel Detheux also recently made the following trade(s):

• On Monday, June 9th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.03, for a total value of $440,136.46.
• On Monday, June 9th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.03, for a total value of $84,252.00.
• On Friday, June 6th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total value of $448,035.22.
• On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total value of $85,764.00.
• On Wednesday, June 4th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $443,218.30.
• On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $84,840.00.

iTeos Therapeutics Stock Up 1.9%

Shares of ITOS stock traded up $0.19 during trading hours on Friday, reaching $10.17. The company's stock had a trading volume of 1,114,742 shares, compared to its average volume of 673,504. The firm's 50 day simple moving average is $7.84 and its 200-day simple moving average is $7.53. The company has a market capitalization of $389.25 million, a price-to-earnings ratio of -3.23 and a beta of 1.51. iTeos Therapeutics, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.14. Sell-side analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Wall Street Analyst Weigh In

ITOS has been the topic of a number of analyst reports. Leerink Partners reissued a "market perform" rating and set a $9.00 price target (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Wells Fargo & Company reissued an "equal weight" rating and set a $12.00 price target (down previously from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Raymond James set a $12.00 price target on iTeos Therapeutics in a research report on Wednesday, May 14th. HC Wainwright downgraded iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Finally, Wedbush downgraded iTeos Therapeutics from an "outperform" rating to a "neutral" rating and raised their target price for the company from $10.00 to $12.00 in a report on Wednesday, May 28th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $15.86.

Institutional Investors Weigh In On iTeos Therapeutics

Several hedge funds have recently modified their holdings of the company. RA Capital Management L.P. boosted its holdings in shares of iTeos Therapeutics by 74.4% during the 1st quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock valued at $21,785,000 after acquiring an additional 1,556,798 shares in the last quarter. BVF Inc. IL raised its position in iTeos Therapeutics by 32.3% during the 1st quarter. BVF Inc. IL now owns 3,075,000 shares of the company's stock worth $18,358,000 after purchasing an additional 750,000 shares during the last quarter. JPMorgan Chase & Co. raised its position in iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock worth $15,888,000 after purchasing an additional 1,601,477 shares during the last quarter. 683 Capital Management LLC raised its position in iTeos Therapeutics by 90.6% during the 1st quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company's stock worth $10,448,000 after purchasing an additional 831,883 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in iTeos Therapeutics by 15.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company's stock worth $9,293,000 after purchasing an additional 163,880 shares during the last quarter. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.